Pharmacyte Biotech Inc (OTCMKTS:PMCB) has been adding a number of honors to its list. PMCB’s contract research organization has been recently voted as Australia’s favorite CRO. Clinical Network Services had been engaged by PMCB as its CRO for preparing the phase 2b clinical trial for its cancer drug. Additionally, the company’s director for the diabetes program, Dr. Eva-Maria, has invited at the Austrodrugs 2015 conference. She has been asked to speak on the company’s cell-encapsulation technology.
It is safe to consider that Pharmacyte is quickly gaining attention, both from the business community and from its competitors. CNS was recently given the award, after being voted for by investigational studies and sponsors of clinical trials. The award confirms that the quality of service and efficiency provided by CNS is top-notch. Pharmacyte was more than happy to have been reassured that it had made the right choice.
Pharmacyte came into the limelight, after successfully developing its proprietary cell-in-a-box technology. Quite a number of biotech companies have tried to crack the secrets of cell-encapsulation and it is considered a vital resource in fighting cancer. Pharmacyte was able to fulfill three very important requirements with regard to cell-encapsulation.
- The encapsulated cell was small enough to be implanted in the human body.
- It can resist the effects of the response from the immune system.
- It is porous enough to allow the healthy cells inside to operate in place of the patients own cells.
These qualities make the encapsulated cell ideal to serve the purpose of drug delivery. The recent invitation to Dr. Eva-Maria to speak at a renowned biotech conference is a sign that the industry and academia both realize the importance of the progress made by PMCB. However, the real challenge for the company would be to make an impact on the market once the drug is ready.
Pharmacyte Biotech Inc (OTCMKTS:PMCB) registered a very slight increase of 0.38% during the June 15 session. A total of 707.77 million PMCB shares were traded in the market to help the stock close at $0.133.